Efficacy of switching between tumor necrosis factor-alfa inhibitors in psoriasis: results from the Italian Psocare registry by Piaserico, S et al.
This Accepted Author Manuscript (AAM) is copyrighted and published by Elsevier. It is
posted here by agreement between Elsevier and the University of Turin. Changes resulting
from the publishing process - such as editing, corrections, structural formatting, and other
quality control mechanisms - may not be reflected in this version of the text. The definitive
version of the text was subsequently published in JOURNAL OF THE AMERICAN
ACADEMY OF DERMATOLOGY, 70, 2014, 10.1016/j.jaad.2013.10.019.
You may download, copy and otherwise use the AAM for non-commercial purposes
provided that your license is limited by the following restrictions:
(1) You may use this AAM for non-commercial purposes only under the terms of the
CC-BY-NC-ND license.
(2) The integrity of the work and identification of the author, copyright owner, and
publisher must be preserved in any copy.
(3) You must attribute this AAM in the following format: Creative Commons BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/deed.en),
10.1016/j.jaad.2013.10.019
The definitive version is available at:
http://linkinghub.elsevier.com/retrieve/pii/S0190962213011043
J Am Acad Dermatol. 2014 Feb;70(2):257-62.e3. 
doi: 10.1016/j.jaad.2013.10.019. Epub 2013 Dec 16.
Efficacy of switching between tumor necrosis factor-alfa inhibitors in psoriasis: Results from the Italian 
Psocare Registry
Stefano Piaserico, MD, PhD,a Simone Cazzaniga, PhD Math,b Sergio Chimenti, MD, PhD,c Alberto Giannetti, 
MD, PhD,d Mara Maccarone,  BA,e  Mauro Picardo,  MD,f Andrea Peserico,  MD,a and Luigi  Naldi,  MD,b 
Psocare Study Group*
Padua, Bergamo, Rome, and Modena, Italy
From the Dermatology Unit, Department of Medicine, University of Padua
a; Centro Studi Gruppo Italiano Studi In Epidemiologia (GISED), Papa Giovanni XXIII Hospital, Bergamo
b; Department of Dermatology, University of Rome ‘‘Tor Vergata’’
c; Department ofDermatology, University of Modena and Reggio Emilia
d; Italian Psoriatic Patient Association (Associazione Difesa Pazienti Psoriasici [ADIPSO]), Rome
e; and Laboratory of Cutaneous Physiopathology, San Gallicano Dermatological Institute Rome.
f*The PSOCARE study centres are listed in the Appendix at http://www.jaad.org.
ABSTRACT
Background: Some studies have shown that switching patients from one tumor necrosis factor (TNF)-alfa
inhibitor to another may be beneficial when they have an inadequate response or an adverse event.
Objective: We sought to assess the variables predicting the efficacy of the second TNF-alfa inhibitor in
patients discontinuing the first TNF-alfa inhibitor.
Methods: Data from all 5423 consecutive patients starting TNF-alfa inhibitor therapy for psoriasis between
September 2005 and September 2010 who were included in the Italian Psocare registry were analyzed. 
Results: In 105 patients who switched to a second TNF-alfa inhibitor who had complete follow-up data, 75% 
improvement in the Psoriasis Area Severity Index score (PASI 75) was reached by 29% after 16 weeks and 
by 45.6% after 24 weeks. Patients who switched because of secondary loss of efficacy (loss of initial PASI 75 
response) or adverse events/intolerance were more likely to reach PASI 75 than those who switched as a 
result of primary inefficacy (PASI 75 never achieved) (hazard ratio 2.7, 95% confidence interval 1.3-5.5 vs 
hazard  ratio  2.0,  95% confidence  interval  1.0-3.9  and  1,  respectively).  Limitations:  There  was  a  small 
number of patients with complete follow-up data.
Conclusion: PASI 75 response in patients who switched from one antieTNF-alfa agent to another was
significantly reduced in patients who showed primary inefficacy of the first antieTNF-alfa. ( J Am Acad
Dermatol 2014;70:257-62.)
Key words: biologics; efficacy; primary inefficacy; psoriasis; secondary loss of efficacy; switching; tumor
necrosis factor-alfa inhibitors.
It  is  well  established  that  tumor  necrosis  factor  (TNF)-alfa  inhibitors  have  markedly  improved  the 
management of psoriasis. Several randomized clinical trials have reported that 50% to 90% of patients are 
likely to experience a short-term improvement in symptom severity when treated with biological agents.1
Patients’  clinical  response to  treatment  with TNF-alfa  inhibitors  has,  nevertheless,  been found to vary 
enormously. Some patients may fail to respond at all to a first cycle of treatment with a TNF-alfa inhibitor 
(primary  inefficacy).  Others  may  respond  well  initially,  but  may  later  show  an  inadequate  response 
(secondary loss of efficacy or acquired drug resistance). Even others may present drug intolerance or other 
adverse events.
It is not uncommon for physicians to switch patients from one TNF-alfa inhibitor to another when there is 
an inadequate response or an adverse event.2  As new biological  agents with different  mechanisms of 
action are becoming available for the management of this condition, clinicians’ and patients’ treatment 
options continue to increase. The optimal therapeutic strategy for patients with an inadequate response
to a first  cycle of biologics remains,  nevertheless,  an unanswered question that  often arises in  clinical 
practice.
The aim of this study was to assess the efficacy of switching to a second TNFalfa inhibitor in patients 
discontinuing  a  first  one  because  of  an  inadequate  response  (primary  inefficacy  or  secondary  loss  of 
efficacy) or to adverse events. The reasons for switching and the efficacy of the second TNF-alfa inhibitor 
used were also evaluated.
METHODS
Setting
Involving 155 dermatology clinics appointed by the Italian Regional Health Authorities (see Appendix at 
http://www.jaad.org) as reference centers for the treatment of moderate to severe psoriasis in Italy, the 
Italian Psocare Registry  was instituted on September 1,  2005.  The ethical  committees  of the hospitals 
contributing to this  registry approved the study protocol.  The registry’s goals and methods have been 
described in detail elsewhere.3
Patients
All  consecutive patients presenting at the participating  centers who were prescribed TNF-alfa inhibitor 
treatment for psoriasis between September 2005 and September 2009 were considered for this study. Only 
adults (aged $18 years) with a clinically confirmed diagnosis of chronic plaque psoriasis or psoriatic arthritis 
were considered eligible for the study. The drug agents used were etanercept, infliximab, and adalimumab.
Patients with a diagnosis of guttate, pustular, or erythrodermic psoriasis at presentation were excluded. 
Those receiving combination therapies (eg, methotrexate associated with TNF-alfa inhibitor treatments), 
receiving off-label dosages (eg, infliximab infusions every 6 weeks, adalimumab injections
every week), and who had unspecified baseline treatments or who were unable to provide Psoriasis Area 
Severity Index (PASI) assessment scores at baseline or during the follow-up period were also excluded.
Patients for whom there was information about the reason the first TNF-alfa inhibitor was discontinued 
were likewise excluded.
After giving their written informed consent, the patients considered eligible were included in the Italian 
Psocare Registry and assigned a distinctive personal code to ensure data anonymity.
Follow-up and data collection Study participants agreed to take part in at least 3 years of follow-up. Data 
were  collected  at  baseline  and  at  regular  intervals  thereafter.  Information  was  gathered  by  the 
investigators using World Wide Webebased electronic data collection forms endowed with internal quality 
controls, which also guaranteed confidentiality.
The data collected at baseline included: (1) patients’ demographic details and personal habits (smoking and 
average alcohol consumption);
(2) patients’ comorbidities and medications;
(3) dermatologic and family history of psoriasis and arthritis; and (4) severity of psoriasis at entry, dosages 
and drugs prescribed, and the results of  laboratory tests performed before their prescription.
The PASI was adopted as the measure of disease severity. A 75% improvement in the PASI score (PASI 75) 
was considered a clinically meaningful improvement.
The following information were collected during follow-up examinations: (1) patients’ demographic details 
and personal habits were updated; (2) psoriasis progression/regression was updated as was medication 
information; (3) any adverse events, new diagnoses, hospitalizations, or examinations by specialists were 
recorded; and (4) laboratory tests and results were recorded.
The reasons for discontinuing prior TNF-alfa inhibitor therapy were classified as follows:
(1) PASI 75 was never achieved (primary inefficacy); (2) loss of initial PASI 75 response (secondary loss of
efficacy); or (3) adverse event or other, including drug intolerance or physician’s decision.
Statistical analysis In all, 105 patients who were switched to second TNF-alfa inhibitor were eligible for the 
study.
For  descriptive  purposes,  continuous  variables  are  presented  here  as  means  with  SD  and  categorical 
variables as numbers with percentages. For univariate and multivariate analyses, continuous variables were 
categorized using tertiles of their distribution as cut-offs. The Kaplan-Meier productlimit estimate was used 
for univariate analysis of the duration of the treatment with a second TNF-alfa inhibitor using a PASI 75 as 
the end point. The log rank test was used to compare cumulative response rates between different levels of 
selected variables.
We also compared the PASI 75 response achieved in the 105 patients who switched therapy with that 
achieved in 2933 patients who did not but were able to provide complete data (body mass index, PASI 
assessment scores, and prescribed treatments) to make adjustments for potential baseline confounders.
All  variables  with  a  P  value  less  than  .10  at  univariate  analysis  were  considered  for  inclusion  in  the 
multivariate analysis. Cox proportional hazards regression with forward stepwise algorithm selection was 
used to identify significant predictor factors of PASI 75 response. The effects of the factors identified were 
expressed in terms of hazard ratios along with their 95% confidence intervals and P values.
A P value less than .05 was considered significant.
The analysis was conducted using software (SPSS, Version 17.0, IBM Corp, Armonk, NY).
RESULTS
Demographic details and treatments Overall 5423 patients who were treated with a first cycle of TNF-alfa 
inhibitors were identified. Of these 1034 (19.1%) were excluded from the study because not all patient data 
needed for this study were available. Of the remaining 4389 patients, 228 switched to a second TNF-alfa 
inhibitor after discontinuing the first one, but salient information about the first treatment (including the 
reason for switching)  and all  outcome assessment values during follow-up were available only for 105 
(Table I).
Adalimumab was found to be more frequently prescribed as a second TNF-alfa inhibitor than as the first 
one. The majority of patients (60% of cases) switched from etanercept to a monoclonal antibody, 20.9% 
switched from a monoclonal antibody to etanercept, and 18.1% switched from one monoclonal antibody to 
another.
The reason for switching to a second TNF-alfa inhibitor was primary inefficacy (PASI 75 never achieved) in 
47 cases (44.8%), secondary loss of efficacy (loss of initial PASI 75 response) in 23 (21.9%), and adverse 
events/other in 35 (33.3%).
Patients who switched had been treated with the first TNF-alfa inhibitor for a mean of 58.4 (637.9) weeks.
Cumulative PASI 75 response A cumulative PASI 75 response rate was attained in 29%, 45.6%, and 74.1% of 
the patients after switching to the second TNF-alfa inhibitor after 16, 24, and 52 weeks, respectively. These 
scores were quite similar to those in patients who did not switch TNF-alfa inhibitors (30.6%, 42.5%, and 
67.5% after 16, 24, and 52 weeks, respectively, P = .090).
After 16 and 24 weeks of treatment with a second TNF-alfa inhibitor, PASI 75 was reached by 14.4% and 
29.8%, respectively, being treated with etanercept; by 26.6% and 40.4%, respectively, being treated with
infliximab;  and  by  38.3%  and  58%,  respectively,  being  treated  with  adalimumab.  Univariate  and 
multivariate analyses on variables associated with the efficacy of the second TNF-alfa inhibitor Univariate 
analysis showed that the reason for switching and the length of time the first TNF-alfa inhibitor was taken 
were associated to the cumulative PASI 75 at 52 weeks. Notably, the cumulative PASI 75 response rates for 
patients stratified according to the reason the first  cycle  of  TNF-alfa  inhibitors was discontinued were 
higher for the those who switched because of: (1) a secondary loss of efficacy; or (2) adverse events, drug 
intolerance,  or  as  a  consequence  of  their  physician’s  decision;  than for  (3)  those  who  had  from  the 
beginning failed to respond to the first TNF-alfa inhibitor (31.4%, 34.3%, and 11.6% at 12 weeks, and 58.4%, 
57.1%, and 30.2% at 24 weeks, respectively) (Fig 1).
Multivariate analysis confirmed the data obtained at univariate analysis, showing a statistically significant
positive correlation between a clinical response (PASI 75) and secondary loss of efficacy as the reason for 
withdrawal (Table II).
DISCUSSION
The findings emerging from this large Italian cohort of patients with moderate to severe psoriasis in whom 
a cumulative  PASI  75  response  was achieved in  29% and 45.6% after  16 and 24  weeks,  respectively, 
confirmed that some patients benefit from switching to a second TNF-alfa inhibitor after the first proves to 
be inefficacious. Most of the patients studied who switched were treated with adalimumab during the 
second cycle and this was to be expected in view of the fact that it was introduced into clinical practice at a 
later date with respect to the other 2 TNF-alfa inhibitors.
Only a limited amount of data is available in the literature concerning patients with psoriasis who switched 
biological agents with the greater part coming from short-term, nonrandomized studies concentrating on 
small population samples.
Those  observational  studies  have,  nevertheless,   described  improved  disease  severity  in  the  patients 
studied2,4-11 although their response rate appeared lower than what might have been expected in clinical 
trials focusing on patients na€ıve to biological agents.
BothWoolf et al12 and Van L€umig et al13 reported a PASI 75 response, respectively, in 29% (at 16 weeks) 
and 27% (at 12 weeks) of the psoriatic patients who switched from etanercept to adalimumab and this 
finding was confirmed by our study, with 14.4%, 26.6%, and 38.3% of our patients reaching a PASI 75 at 16 
weeks who were being, respectively, treated with etanercept, infliximab, and adalimumab.
The  differences  in  response  to  several  TNF-alfa  inhibitors  can  be  linked  to  the  differences  in  their 
bioavailability  and  stability  and  in  patients’  genetics.  These  drugs  also  differ  in  terms  of  their 
immunogenicity or potential to induce antidrug antibodies, which may be associated to a secondary loss of 
response over time.
Nearly all published studies on patients switching from one TNF-alfa inhibitor to another failed to analyze 
the reasons for abandoning the first.
Biological treatment is considered a failure when: a patient does not respond to treatment at all (primary 
inefficacy),  when  the  patient  shows  secondary  loss  of  efficacy  with  time after  an  initially  satisfactory 
response (this may be a result of the production of antibodies against the drug),14-16 or when a patient 
develops an intolerance to the biological agent (with drug reactions or various adverse events, which may 
differ in the 3 TNF-alfa inhibitors considered).
Some studies on patients with rheumatoid arthritis and ankylosing spondylitis did, nevertheless, indicate 
that the response to a second TNF-alfa inhibitor seems to differ depending on the reason the first one was 
abandoned. A second TNF-alfa inhibitor might be more effective in patients with a history of secondary loss 
of efficacy than in those with a primary inefficacy.17-20 In our study, achieving a PASI 75 response was, 
indeed, significantly associated with the reason for switching: patients with secondary loss of response or 
adverse events/intolerance achieved a PASI 75 response more often than those who failed to respond to 
the first  TNF-alfa  inhibitor.  This  correlation was confirmed by  the 2  studies  on psoriatic  patients  who 
switched biological agents that did examine the reason for discontinuing the first cycle.11,13 In particular, a 
subanalysis of the double-blind, randomized, controlled BELIEVE trial showed that 53.8% of patients who 
had previously not responded at all to a prior antieTNF treatment achieved a PASI 75 by week 16 as did 
65.7% of the patients with a history of an initially satisfactory response that was lost.11 The fact ours was a 
prospective, observational, cohort study of patients with psoriasis attending dermatology clinics and that 
the  choice  of  treatment  was  not  randomized  but  at  the  discretion  of  the  treating  physician  can  be 
considered study limitations; likewise the fact that data needed to carry out our analyses were available for 
only a small proportion of the patients.
In  conclusion,  this  prospective,  open,  registrybased  study  shows  that  switching  to  a  second  TNF-alfa 
inhibitor can be effective in some psoriatic patients, particularly in cases of a secondary loss of response to 
a previous TNF-alfa inhibitor or to drug intolerance.
Improvement in symptom severity in patients with a history of primary inefficacy is of course advantageous 
and desirable despite a debatable cost-benefit profile. Using a drug with a different mechanism of action 
seems opportune in these cases  in  view of  the patients’  lower rate of  response to a  second TNF-alfa 
inhibitor with respect to that noted in patients continuing with the first. Needless to say, treatments should 
always be tailored to each patient’s needs taking into account his/her characteristics (traditional drug use 
and tolerance, comorbidities, weight) and preferences (mode and frequency of drug administration) and,
when it comes to switching from a TNF-alfa inhibitor to another drug, the reason the first was discontinued.
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Table I. Demographics, and disease and treatment characteristics of 105 patients who 




Male (%) 68 (64.8)
Female (%) 37 (35.2)
Age, y, mean (SD) 47.4 (12.5)
BMI, mean (SD) 28.8 (5.6)
PASI score on starting first TNF-alfa 18.1 (12.6)
    inhibitor [baseline], mean (SD)
PASI score on starting second TNF-alfa 8.8 (8.4)
     inhibitor [switch], mean (SD)
Time on first TNF-alfa inhibitor [baseline], 58.4 (37.9)
    mean (SD)
≤24 wk 16 (15.2%)
>24 wk 89 (84.8%)
Time on second TNF-alfa inhibitor 29.0 (26.4)
    [switch], wk, mean (SD)









Adalimumab to etanercept 4 (3.8%)
Adalimumab to infliximab 1 (1.0%)
Etanercept to adalimumab 25 (23.8%)
Etanercept to infliximab 38 (36.2%)
Infliximab to adalimumab 18 (17.1%)
Infliximab to etanercept 19 (18.1%)
Total 105
____________________________________________________________________
BMI, Body mass index; PASI, Psoriasis Area Severity Index; TNF,
tumor necrosis factor.
Table II. Multivariate analysis of variables associated with a 75% improvement in the Psoriasis
Area Severity Index score response
___________________________________________________________________________




Secondary loss of efficacy      2.7 (1.3-5.5) .008
Adverse events/other      2.0 (1.0-3.9) .037
Time on first TNF-alfa inhibitor, wk
≤35      2.1 (1.1-4.1) .035
35-65 1
>65      2.9 (1.4-5.7) .003
___________________________________________________________________________
CI, Confidence interval; TNF, tumor necrosis factor.
Fig 1. Cumulative 75% improvement in the Psoriasis Area Severity Index score (PASI75) response stratified
according to the reason the first tumor necrosis factor-alfa inhibitor was discontinued.
